Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rhizen Pharmaceuticals S.A.

http://rhizen.com/

Latest From Rhizen Pharmaceuticals S.A.

Calithera’s Telaglenastat Doubles PFS In Proof-Of-Concept Study

The US biotech’s product becomes the first glutaminase inhibitor to show proof of concept. Calithera now awaits data from a larger registrational study next year in renal cell carcinoma.

Clinical Trials Companies

Pacts In Medtech: March/April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bi-monthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in March and April 2017.

Deals Pacts in Medtech

TG Therapeutics Builds A Business Model For Today

The speed with which TG Therapeutics burst on the scene, along with the impressive potency and safety of its novel combinations of cancer drugs, has perhaps blinded observers to the unique business model that has carried it this far.

BioPharmaceutical Strategy

Device/Diagnostics Quarterly Deal Statistics, Q1 2015

Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.

Medical Device Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register